General Information
Drug ID
DR00044
Drug Name
Topotecan
Synonyms
(4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin; Hycamptamine; Hycamptin; Hycamtamine; Hycamtin; Hycamtin (TN); SK&F-104864-A; SKF 104864; SKF-104864-A; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan Monohydrochloride, (S)-Isomer; Topotecan [INN:BAN]; Topotecan lactone; Topotecane; Topotecane [INN-French]; Topotecanum; Topotecanum [INN-Latin]
Drug Type
Small molecular drug
Indication Ovarian cancer [ICD11: 2C73] Approved [1]
Therapeutic Class
Anticancer Agents
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=60700"></iframe>
3D MOL 2D MOL
Formula
C23H23N3O5
Canonical SMILES
CCC1(C2=C(COC1=O)C(=O)N3CC4=C(C3=C2)N=C5C=CC(=C(C5=C4)CN(C)C)O)O
InChI
InChI=1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1
InChIKey
UCFGDBYHRUNTLO-QHCPKHFHSA-N
CAS Number
CAS 119413-54-6
Pharmaceutical Properties Molecular Weight 421.453 Topological Polar Surface Area 103
Heavy Atom Count 31 Rotatable Bond Count 3
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 7
PubChem CID
60700
PubChem SID
103170619 , 103922004 , 103942242 , 104321416 , 11409161 , 11459078 , 11461196 , 117586312 , 124878927 , 124878928 , 126631363 , 126682466 , 129347572 , 13340 , 134337938 , 135026276 , 135610141 , 136342520 , 136376449 , 137007926 , 137275799 , 142090317 , 144220376 , 14807035 , 14904851 , 152106211 , 152198470 , 160660968 , 160964365 , 24769902 , 43118056 , 46505204 , 47348955 , 47499101 , 47572929 , 48242924 , 50028360 , 50123362 , 53790588 , 56311903 , 57314070 , 581639 , 606579 , 78527173 , 7890901 , 7980817 , 8187013 , 92309036 , 92710943 , 96025302
ChEBI ID
CHEBI:63632
TTD Drug ID
D02PMO
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
MATE1 Transporter Info Multidrug and toxin extrusion protein 1 Substrate [3]
MATE2 Transporter Info Multidrug and toxin extrusion protein 2 Substrate [3]
MRP1 Transporter Info Multidrug resistance-associated protein 1 Substrate [4]
MRP4 Transporter Info Multidrug resistance-associated protein 4 Substrate [5]
P-GP Transporter Info P-glycoprotein 1 Substrate [6]
Drug-Transporter Activity Data
Drug-Transporter Activity Data BCRP Transporter Info Km = 213 microM Madin-Darby canine kidney cells (MDCKII)-BCRP [6]
MATE1 Transporter Info Km = 70 microM Human embryonic kidney cells (HEK293)-MATE1 [3]
MATE2 Transporter Info Km = 60 microM Human embryonic kidney cells (HEK293)-MATE2K [3]
MRP4 Transporter Info Km = 1.66 microM Human liver cancer cells (HepG2)-MRP4 [5]
P-GP Transporter Info Km = 78.3 microM Human enterocyte-like 2 cells (Caco-2)-MDR1 [6]
P-GP Transporter Info Km = 102 microM Madin-Darby canine kidney cells (MDCKII)-MDR1 [6]
References
1 Topotecan was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C. Eur J Pharmacol. 2010 Oct 10;644(1-3):41-8.
3 Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
4 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
5 Topotecan is a substrate for multidrug resistance associated protein 4. Curr Drug Metab. 2006 Jan;7(1):105-18.
6 Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells. Pharm Res. 2008 Nov;25(11):2601-12.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.